Worldwide Gene Expression Analysis Market Witness A Remarkable Growth Projected By 2023

 Market Highlights

Global biologic market is expected to grow at a CAGR of 8.6% during forecasted period 2017-2023 and reach till $425 million by end of 2023. Biologics are the drugs prepare or obtain from the biological organism. They are composed of protein, sugars or nucleic acids.  This drugs are basically used in treatment of cancer and diabetes. Increasing prevalence of these diseases across the globe is the major responsible factor for the growth of the market. Beside this increasing demand for the better treatment, rising regulatory convergence and better access to healthcare for all nations has provided fuel for the growth of the market. On the other hand, biologic drugs are highly complex in nature and they must be controlled under maintained condition. This type of atmosphere and quality control is very difficult and requires a huge capital. This may hamper the growth of the market.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6911 

On regional basis, global biologic market is segmented as North America, Europe, Asia Pacific and Middle East and Africa. Almost 9% of total North America population is suffering from diabetes.  North America shares nearly half of the global biologic market due to increasing diabetic and cancer population, increasing healthcare expenditure and governmental support for the research and development. North America is followed by Europe. UK and Germany are the major contributor for the biologic market. Asia Pacific is the fastest growing region for the biologic market due to rapid development of health care sector and presence of rapidly growing economies like India and China. While Middle East and Africa has the least biologic market.

Segmentation:

Global biologic market is segmented on the basis of type into vaccines, blood products, proteins, gene therapy, and other. On the basis of application they are segmented into anemia, cancer, diabetes, and other. On the basis of source they are segmented as human, animal, microorganism, and other.

Some of the major players in the global neuromodulation market include Unilife Corporation (US), Sanofi (France), Retractable Technologies Inc. (US), Smiths Medicals (UK), Becton, Dickinson & Company (Germany), Terumo Corporation (Japan), Pfizer Inc. (US), Roche Diagnostics (Switzerland), Amgen (US), GSK Biologicals (UK), Lundbeck (Denmark), Novartis AG (Switzerland), AstraZeneca (UK), Bayer AG (Germany), Genzyme (US), Merck KGaA (Germany), Samsung Biologics (South Korea), Celltrion (South Korea), Addgene (US), Johnson & Johnson Inc. (US), Eli Lilly & Company (US), Bristol-Myers Squibb (US), Biogen Inc. (US).

Many of the major companies are focusing on introduction of new biologic drugs and advancement in the treatment of the diseases by minimizing the side effects of the drugs.

Unilife Corporation is a U.S. based developer, manufacturer and supplier of injectable drug delivery services. Precision-Therapy, Flex-Therapy, Imperium are the widely used injectors of this company.

Sanofi is a French multinational pharmaceutical company headquartered in France. This company has performing phase 3 trials on efpeglenatide and sotagliflozin for the treatment of diabetes and isatuximab for the treatment of Multiple Myeloma in 2017. ActHIB, DAPTACEL, Fluzone High-Dose and Imovax Rabies are some of the vaccines manufactured by this company.

Becton, Dickinson & Company a Germany headquartered company has introduced BD Neopak a prefillable glass syringe designed for high-volume injection of biologics.

Smiths Medicals an UK headquartered company is one of the leading pharmaceutical manufacturing and research company. Varivax SDV, Menactra VL, Adacel SYR and Decavac SYRG are some of the major vaccines of this company.

Eli Lilly & Company is a U.S. based pharmaceutical company. This company has recently got an approval for Olumiant for the treatment of Arthritics.

AstraZeneca an UK headquartered company has announced positive top-line results for its licensed asthma biologic benralizumab. Arimidex (anastrozole) and Casodex (bicalutamide) are some of the major drug by the company for the treatment of Cancer.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/biologics-market-1339 

Microcarriers Market Sparkling Growth Worldwide Forecasts By 2023

 

Market Highlights:

The Global Microcarrier Market is anticipated to hold a market value of USD 1.18 billion with an estimated CAGR of 5.9% during the forecast period. A microcarrier is a support matrix allowing the growth of adherent cells. The microcarrier system provides high cell yields without having to resort to bulky equipment and tedious methodology. The rise in the use of microcarrier technology for various cell-based applications, coupled with the advantages of the microcarrier system such as its support for high yield of cells, facilitation of polarization and differentiation of cells, and lower risk of contamination are expected to drive the growth of the market during the forecast period. Moreover, the rapid growth of the biologics industry also fuels the growth of this market. On the other hand, strict regulatory framework, and limitation in production of high-density cell culture may hinder the growth of the market during the forecast period.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6911 

The global microcarrier market is currently dominated by many market players. These players are engaged in new product launches and strategic collaborations to strengthen its market position. For instance, in March 2018, Danaher announced that it has entered into a definitive agreement to acquire Integrated DNA Technologies, a privately-held provider of high-value consumables for genomics applications in next generation sequencing, synthetic biology, molecular biology, gene editing and molecular diagnostics.

Regional Analysis:

The market in the Americas is expected to dominate the global Microcarrier market during the forecast period owing to the increasing incidence of cancer and other chronic diseases, a well-developed healthcare sector and growing number of venture capital investments. According to data published by Centers for Disease Control and Prevention (CDC), 1,633,390 new cases of cancer were reported in the year 2015, and 595,919 people died of cancer in the United States in the same year. The European market is expected to be the second-largest due to government funding and support of the healthcare sector coupled with the strategic expansion of biopharmaceutical companies in this region. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing during the assessment period owing to growing disposable income and rising demand for cell-based vaccines. The market in the Middle East and Africa is likely to account for the smallest share of the global microcarrier market. The market growth in this region can be attributed to the growing government initiatives.

Segmentation:

The global microcarriers market has been segmented into product type, application, and end-user.The market, on the basis of type, has been segmented into equipment, and consumables.The market, based on equipment, has been segmented into bioreactors, culture vessels, cell counters, filtration systems, and other equipment.The market, based on consumables, has been sub-segmented into media, reagents, and microcarrier beads.The market, based on media, has been further segmented into serum-based media, serum-free media, and other media.

The market, based on microcarrier beads, has been sub-segmented into cationic microcarriers, collagen-coated microcarriers, protein-coated microcarriers, and other microcarrier beads.The market, on the basis of application, has been further segmented into vaccine manufacturing, cell therapy, biologics manufacturing, and other applications.The market, on the basis of end-user, has been further segmented into pharmaceutical and biotechnology companies, research institutes, and contract research organizations.

Key Players

Some of the key players in the global microcarrier market are Thermo Fisher Scientific Inc., Lonza, GENERAL ELECTRIC COMPANY, Corning Incorporated, Sartorius AG, Danaher, Merck KGaA, Becton, Dickinson and Company, Eppendorf AG and HiMedia Laboratories.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/microcarriers-market-6911 

The Forensic Swab Market Grows Incredibly; Confirms Mrfr Unleashing Industry Prognostications Up To 2023

 

Forensic Swab Market Overview:

The use of forensic swabs is gaining traction with the broadening of its applications. Swabs have been in usage for common applications, but their usage in forensic applications is one of the key reasons that is boosting the demand for the market. As per a report published by MRFR on the global forensic swab market, the market is expected to achieve a CAGR of 5.8% while accumulating revenues worth USD 49.09 Mn in the period of the forecast from 2018 to 2023. The market is expected to witness notable development due to the presence of notable players who are modifying the competitive landscape favorably.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/6929

The development of the forensic swab market is centered on the demand that is being generated from the forensic and medical sector primarily. The rise in crime rates worldwide entails an increased level of usage of swabs to conduct examinations to increase the accuracy of profiling. Moreover, the use of swabs to carry out medical tests for various conditions is increasing the development of the forensic swabs market. The use of genetic material in a criminal investigation to deal with questions pertaining to legal situations, such as criminal and civil cases is also increasing the demand for forensic swabs globally. Furthermore, the intensifying usage of forensic biotechnology in the administration of justice is raising the development pace of the market.

Additionally, the escalated level of spending from the government is anticipated to bolster the evolution of the market. Also, the expansion of the market into the untapped regional markets is forecasted to boost the level of development that can be achieved from the market. The market is projected to be restrained by the high costs DNA free forensic swabs and the relatively irregular supply of new products in the market.

Segmental Analysis

The segmental analysis of the forensic swab market is segmented on the basis of type of swab shaft, type, end-user, and region. On the basis of type, the forensic swab market is segmented into foam, flocked, and cotton tips. The foam type segment was found to be heading the market segment in 2017. The cotton swabs segment is projected to witness the highest CAGR through the forecast period. The segmentation on the basis of types of swab shaft segments the forensic swab market into wood stick shaft, polystyrene shaft, and others. The polystyrene shaft was found to be the topmost market portion in 2017 and is expected to observe the highest CAGR in the duration of the forecast period. The end user based segmentation of the market comprises of hospitals, forensic science laboratories, among others. The forensic science laboratories segment was in charge of the market in 2017 and is projected to carry on with its control in the forecast period.

Detailed Regional Analysis 

The regions of Europe, the Americas, Asia Pacific, and the Middle East and Africa are included in the regional analysis of the forensic swab market. The Americas region is responsible for the major market share in 2017 and is projected to control the forensic swab market. The Americas region is accredited for the principal regional market share due to factors such as the mounting number of forensic labs in the region, increasing number of criminal cases, and increased dependence on blood sampling. The rise in the number of forensic labs in the regions has also contributed to a growth in the number of microbiological tests. The development of laboratories in hospitals is also anticipated to support the forensic swab market in this region.

The European region is accountable for the ensuing principal market share in 2017. The expansion of the region is attributed to the increasing number of research labs and hospitals, and the escalation in accident cases is expected to boost the demand for swabs through the forecast period. The Asia Pacific region is estimated to exhibit a CAGR of 6.1% through the forecast period owing to the rising frequency of various diseases, demand for blood sampling, and an increasing number of forensic labs being set up in the region. On the other hand, the Middle Eastern and African region are estimated to see decelerated growth due to the restricted exposure to forensic labs and the low awareness levels in this region.

Competitive Analysis

The global forensic swab market’s growth is expected to be highlighted by the intense competition, frequent changes in government as well as rapid advances in the product mix.  The points related to cost, reliability, and quality of the products are expected to improve the chances for the growth of the manufacturers. The efforts undertaken to enhance the market dynamics such as improvement of infrastructure is expected to benefit the progress of the market in the long term. Thermo Fisher Scientific Inc., Sirchie, Merck KGaA, Copan Italia S.p.A., SARSTEDT AG & Co. KG, MWE, Luna, Puritan Medical Products, Becton, Dickinson and Company, and Medtech Forensics are some of the market players included in the report.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/forensic-swab-market-6929  

Chronic Lymphocytic Leukemia Treatment Market 2020 - Shares, Revenue, Analysis And Forecasts Till 2023

 Market Scenario

As per the data experts at Market Research Future (MRFR), the chronic lymphocytic leukemia treatment market was worth USD 7.9 Billion in 2017. Additionally, the market is expected to expand at a growth rate of 19% over the forecast period (2018-2023).

Market Drivers and Key Challenges

Chronic lymphocytic leukemia is considered to be one of the most common types of leukemia in adults. This type of cancer involves the development of lymphocytes, which are white blood cells, within the bone marrow. The lymphocytic leukemia cells are generally present in the lymph nodes along with various other tissues. There are two primary types of chronic lymphocytic leukemia, wherein one grows slowly, and the other is considered fatal. In general, one does not experience any symptoms due to chronic lymphocytic leukemia for a long period. However, the symptoms usually noted include fatigue, easy bruising, and swollen lymph nodes.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6900 

Generally, the most popular form of treatment for CLL is chemotherapy, whereas stem-cell transplant is for rare cases. An article published by Apollo Hospitals states that in India, roughly one million cases of chronic lymphocytic leukemia are diagnosed annually. As per the cancer statistics, 1 in every 155 men and 1 in every 260 women get affected with CLL in their lifetime, in the United Kingdom (U.K). The boost in cancer cases around the world, innovations in drug therapy, quick regulatory approval processes, and vigorous pipeline of drugs for chronic lymphocytic leukemia treatment are additional factors substantiating the growth of the chronic lymphocytic leukemia market.

Having said that, the stunted level of awareness with regard to symptoms is expected to retard the market growth in the forthcoming years. However, growing research & development activities coupled with continuous technological developments in the field is presumed to augment the market growth to a large extent.

Market Segmentation

The global chronic lymphocytic leukemia treatment market has been segmented on the basis of type, treatment, and end user.

The market, in terms of the type, has been considered for indolent CLL and aggressive CLL.

The market, treatment-wise, can be broken down into chemotherapy, targeted drug therapy, immunotherapy, and bone marrow transplant.

The end users in the global market are hospitals & clinics, diagnostic laboratories, research institutes, and others.

Prominent Players

The prominent vendors within the worldwide chronic lymphocytic leukemia treatment market include Teva Pharmaceutical Industries Ltd., Novartis AG, AstraZeneca, Genmab A/S, TG Therapeutics, Inc., Ziopharm Oncology, F. Hoffmann-La Roche Ltd, AbbVie Inc., Genentech, Inc., Gilead, Genzyme Corporation, ONO PHARMACEUTICAL CO., LTD., GlaxoSmithKline plc, CELGENE CORPORATION, Inc., Johnson & Johnson Services, Inc., and others.

Browse Full Report Details @ https://www.marketresearchfuture.com/reports/chronic-lymphocytic-leukemia-treatment-market-6900

Worldwide 3D Printing Medical Devices Market Witness A Remarkable Growth Projected By 2023

 3D Printing Medical Devices Market Overview

As per Market Research Future (MRFR) analysis, the global 3D printing medical devices market is projected to grow at a CAGR of 18% from 2018 to 2023 (forecast period). 

3D printing plays a vital role in the development of medical and dental devices. 3D printing is the most commonly used medical device and, due to its versatility, can also be used for other items, including food, household items, and automotive parts. The 3D printing technology is used to treat various types of therapies, such as hip and jaw titanium replacements, limb prosthetics and plastic tracheal splints, etc. Due to advanced technology and easy use of devices, many doctors prefer 3D printing devices before surgeries of any organ part that may minimize error. A computer-aided design drawing or a magnetic resonance image is a 3D object created from a digital 3D image. The 3D object is formed by creating successive layers of material in which each layer is connected to the previous layer until the object is complete. Various types of materials are used to create a 3D image. 

Get a FREE Sample with Complete TOC @ https://www.marketresearchfuture.com/sample_request/6830

3D Printing Medical Devices Market Dynamics 

The global market for 3D printing medical devices is expected to expand due to growing government spending in the healthcare sector, rising technological developments in 3D printing, easy production of medical devices, and the growing use of 3D printing devices in the healthcare sector. 3D printing plays a crucial role in the medical and dental manufacturing market. This is a very cost-effective and preferred choice for medical device manufacturers for all kinds of medical devices such as prostheses, hearing aids, custom knee, and hip implants. The 3D printing medical devices are expected to show substantial growth during the forecast period due to various technological developments in this field. In addition, a variety of other factors, such as investment in R&D, rapidly growing consumer base, increasing the reach of biomedical applications, have driven market growth. 

However, some aspects that may hinder future market growth are unfavorable reimbursement policies, high printer costs, biocompatibility issues for 3D printed medical devices, and limited technical knowledge in medical devices. 

3D Printing Medical Devices Market Segmentation 

The global market for 3D printing medical devices has been segmented into types, components, technology, application, and end-users. 

Based on types, the global market for 3D printing medical devices is classified into the segments of surgical guides, prosthetics & implants, surgical instruments, and tissue engineering products. The Surgical Guide is predicted to hold the largest share of the 3D printing market for medical devices in the forecast period. The 3D printing surgical guide is part of operation preparation and offers precise restoration of the implant. The demand for a surgical guide is therefore growing which is a significant factor driving the growth of this market segment. 

Based on components, the global market for 3D printing medical devices is divided into materials software & services, 3D printer, and 3D bioprinter. Software & services are projected to register for the largest market share in 3D medical device printing in the forecast period. Growing development of software solutions for the production of high-quality 3D-printed medical products is a primary driver of the growth of the services and software segment. 

On the basis of technology, the market for 3D printing medical device is segmented into 3D printing, droplet deposition, laser beam melting, photopolymerization, laminated object manufacturing (LOM), electron beam melting (EBM), polyjet technology and others. Photopolymerization is projected to maintain the largest market share in the 3D printing medical device.  

Depending on the application, the global 3D printing medical device market is segmented into external wearable devices, implants and tissue engineering, and clinical trial devices. The external wearable devices segment retains the largest share of the 3D printing medical devices market in the forecast period. 

Depending on end-users, the global 3D printing medical device market is categorized into hospitals, medical and surgical centers, pharmaceutical and biotech firms, academic institutions, and contract research organizations. The segment of medical and surgical centers accounts for the largest share of the 3D printing medical devices market due to an increasingly growing patient population and reduced risk of surgery and infection. 

3D Printing Medical Devices Market Regional Analysis 

The market has been segmented by area across the Americas, Europe, the Asia Pacific and the Middle East and Africa. The market for 3D printing medical device in the Americas has been further broken down into North America and South America, with the North American market split into the USA and Canada. The European market for 3D printing medical devices has been segmented into Western Europe and Eastern Europe. Western Europe has also been listed as Germany, France, the United Kingdom, Italy, Spain, and the rest of Western Europe. The market for 3D printing medical devices in the Asia Pacific has been segmented into China, Japan, India, Australia, South Korea, and the rest of the Asia Pacific. The market for biomaterials in the Middle East and Africa has been segmented into the Middle East and Africa. 

North America dominates the market for global 3D printing medical devices over the forecast period. The largest share is due to a growing demand for organ transplantation across the region. Some of the aspects responsible for market growth in this region are attributed to increased government spending to develop advancements in 3D printing technologies and applications. 

The second-largest 3D printing medical devices market is projected to be the European market. Market growth in this region can be ascribed to government funding and support for the healthcare sector, combined with increased research and development. In addition, an increasing number of surgeries due to changing lifestyles are leading to the growth of the market in the region. 

The Asia Pacific is predicted to be the fastest-growing 3D printing medical device market in the forecast period due to the rising prevalence of chronic diseases, increasing investment in healthcare, growing geriatric population, and the proliferation of market players in the region. 

The market in the Middle East and Africa is projected to register for the smallest share of the market for global 3D printing medical devices due to underdeveloped healthcare, lack of technological expertise and inadequate medical facilities. 

3D Printing Medical Devices Market Key Players  

Some of the prominent players in the market for 3D printing medical devices are SLM Solutions Group AG, 3D Systems Corporations, Stratasys Ltd., EnvisionTEC, Arcam AB, Organovo Holdings, Inc., Materialise NV, Oxford Performance Materials, Inc., Bio3D Technologies, Prodways Group, Cyfuse Medical K.K.EOS GmbHConcept, Laser GmbH, 3T RPD Ltd, Renishaw plc.

Obtain Premium Research Report Details @ https://www.marketresearchfuture.com/reports/3d-printing-medical-devices-market-6830 

The Controlled Release Drug Delivery Market Grows Incredibly; Confirms Mrfr Unleashing Industry Prognostications Up To 2023

 Controlled Release Drug Delivery Market Highlights

Controlled release drug delivery provides drug-encapsulating devices from which therapeutic molecules are released at a controlled rate for a period of time, that can be adjusted from days to months. These products are applicable for all age group, but it is highly preferred for the old age and pediatric population to reduce to dose and administer a uniform amount of drug. The key factors responsible for driving this market are growing R&D in the healthcare industry, increasing deaths due to overdose, and rising health-related problems due to the high dose.
Controlled release drug delivery maintains the plasma concentration for various treatment for a period of time. There are different innovative techniques by which the drug can be delivered in controlled amounts. The various ways could be oral form, through nasal, injection and many more, but the oral route is more preferred compared to other form.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6794 

The controlled release drug delivery market was estimated USD 31.96 billion in 2017 and expected to reach USD 70.15 billion by 2023 at a CAGR of 14.0% during the forecast period. However, factors such as less awareness and higher cost per dosage may hinder the market growth during the forecast period.

Segmentation
The global controlled release drug delivery market is segmented on the basis of route of administration, release mechanism, products, and end user.
By route of administration the market is segmented into oral, injectable, ocular, nasal, topical and implantable. The injectable is sub-segmented into targeted delivery, transmucosal, and transdermal. On the basis of release mechanism, the market is segmented into polymer-based drug delivery systems, micro-reservoir partition-controlled drug delivery systems, feedback-regulated drug delivery systems, activation modulated drug delivery systems, and chemically activated controlled drug delivery systems. The activation modulated drug delivery systems are sub-segmented into osmotic pressure activated drug delivery, hydrodynamic pressure activated drug delivery, vapor pressure activated drug delivery, mechanically activated drug, magnetically activated drug. The chemically activated controlled drug delivery systems are sub-segmented into pH-activated drug delivery, hydrolysis activated drug delivery, enzyme activated drug delivery.
On the basis of products, the market is segmented into metered dose inhalers, needle-free injectors, auto-injectors, nasal sprays, transdermal patches, nebulizers, infusion pumps, drug-eluting stents, sustained release, and ocular implants. By end user, the market is segmented into hospital and clinics, personal use, research centers, and others.


Regional Analysis
The Americas is expected to lead the global controlled release drug delivery market owing to the increasing government support for the development of controlled release drug delivery and rising investments in research & development are enhancing the market growth in the region. The increasing prevalence of chronic diseases such as diabetes, cancer, respiratory diseases, Alzheimer’s, etc. are also contributing the market growth. According to the National Cancer Institute, it is estimated that 1,735,350 people will be diagnosed with cancer and 609,640 adults will die in the US in 2018. The increasing number of a cancer patient may boost the market growth in this region.
Europe holds the second largest market for controlled release drug delivery during the forecast period. The rising number of New Drug Application (NDA) and Abbreviated new drug application (ANDA) applications in the region is also supporting and playing a significant role in the growth of the regional market. Apart from this, the rising geriatric population in Europe enhances the market. According to the Office for National Statistics 2017, the UK population is getting older with 18% aged 65 and above and 2.4% aged 85 years. The increasing in aging may boost the controlled release drug delivery market.
Asia-Pacific was expected to be the fastest growing region for the global controlled release drug delivery market. The market is expected to observe high growth owing to the increasing support by government and private funding agencies for the development of healthcare products and increasing expansion in pharmaceutical industries by India, Japan and China support the market growth in this region.
The Middle East and Africa holds the lowest share for controlled release drug delivery market due to the less per capita income and fewer healthcare facilities. However, the growing campaigns for creating awareness about healthcare facilities may increase the market growth in the Middle East and Africa.

Key Players
Some of the key players in the global controlled release drug delivery market are Depomed, Inc. (US), Coating Place, Inc.(US), Corium International Inc.(US), Alza Corporation (Johnson & Johnson)(US), Pfizer Inc.(US), SKY Pharmaceuticals Pvt. Ltd.(China), AstraZeneca (US),Biogen (US), GlaxoSmithKline (UK), Novartis (UK), Allergan (‎Ireland), Collegium Pharmaceutical(US), and others.

FOR MORE DETAILS –  https://www.marketresearchfuture.com/reports/controlled-release-drug-delivery-market-6794 

The Biologics Safety Testing Market Grows Incredibly; Confirms Mrfr Unleashing Industry Prognostications Up To 2023

 

Market Highlights:

The global biologics safety testing market held a value of USD 2.79 billion in the year 2017 and is expected to register a CAGR of 13.6% during the forecast period. Biologics safety testing is required for all biopharmaceutical products and vaccines to ensure the product is safe and free of contaminants.

Growing pharmaceutical and biotech industry and increasing demand for biological products are expected to drive the growth of the market. However, stringent government regulations for the approval of biosimilars and high cost of drug development are likely to hamper the market growth over the forecast period.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/6800 

Regional Analysis:

Geographically, the Americas is expected to dominate the global market owing to the presence of well-established players and rising demand for biological products. Europe is expected to hold the second largest position in the global market owing to the growing pharma and biotech industry. Asia-Pacific is expected to be the fastest growing market owing to the increasing demand for biologics products. Furthermore, the Middle East and Africa region is expected to account for the least market share in the global market.

Segmentation:

The global biologics safety testing market has been segmented into product, test type, and application.

Based on product, the market is segmented into kits & reagents, services, and instruments. The kits & reagents segment is expected to account for the largest share segment of the global market in 2017.

Based on test type, the market is segmented into sterility tests, endotoxin tests, cell line authentication and characterization tests, residual host contamination detection tests, adventitious agent detection tests, bioburden tests, and others.

Based on application, market segmented into vaccine and therapeutics development, blood and blood-related products testing, cellular and gene therapy, tissue and tissue-related products testing, and stem cell research.

Key Players:

Some of the prominent players in the global biologics safety testing market are Merck KGaA, Charles River Laboratories, Sartorius AG, Lonza Group Ltd., SGS S.A., Thermo Fisher Scientific Inc, Wuxi Apptec, Cytovance Biologics, Inc., Avance Biosciences Inc., and Eurofins Scientific.

FOR MORE DETAILS –  https://www.marketresearchfuture.com/reports/biologics-safety-testing-market-6800